Runda Medical's Q1 report shows revenue decline, strategic shifts

Shanghai Runda Medical Technology (SSE:603108) reported a revenue decline in its first quarter of 2025, with revenues totaling CNY 1,661.85 million, a 19.81% decrease compared to the same period last year. The company attributes this downturn to the impact of domestic centralized procurement policies, which led to lower product pricing. While facing revenue headwinds, Runda is focused on its "stable foundation, innovative development" strategy, expanding its focus on AI and proprietary technology development. The company also announced that they would postpone the "integrated service expansion program" with 2020 publicly issued convertible bonds, to complete in 2026. The decision was made out of caution for performance, and the program is supported by a maximum of CNY 399 million.